Meeting
2021 Genitourinary Cancers Symposium
PD-L1 inhibition with avelumab plus abiraterone acetate or enzalutamide in African Americans with metastatic castrate-resistant prostate cancer (mCRPC).
Authors
Jodi Lyn Layton
Tulane University School of Medicine, New Orleans, LA
Jodi Lyn Layton , Charlotte Manogue , Malcolm Light , Ellen Jaeger , Patrick Cotogno , Elisa Marie Ledet , Brian E. Lewis , Pedro C. Barata , A. Oliver Sartor
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Prostate Cancer - Advanced Disease
Track
Prostate Cancer - Advanced
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03770455
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 87)
DOI
10.1200/JCO.2021.39.6_suppl.87
Abstract #
87
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
Efficacy of the PD-L1 inhibitor avelumab in neuroendocrine or aggressive variant prostate cancer: Results from a phase II, single-arm study.
First Author: Landon Carter Brown
Poster
2020 ASCO Virtual Scientific Program
Radiographic paradoxical response in patients with metastatic castrate-resistant prostate cancer (mCRPC) undergoing treatment with second-generation hormone therapy (second-HT).
First Author: Jamal Alamiri
Poster
2017 ASCO Annual Meeting
Combination of PDL-1 and PARP inhibition in an unselected population with metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Fatima Karzai
Poster
2023 ASCO Genitourinary Cancers Symposium
Real-world effectiveness of darolutamide in metastatic castration-resistant prostate cancer: Experience from a safety-net hospital serving a racially and ethnically diverse patient population.
First Author: Alyssa Liang